Associate Professor of Pathology & Laboratory Medicine, School of Medicine
Program Director, Hematopathology Fellowship
Medical Director, Immunohistochemistry Lab
B.S., 2001, Indiana University
M.D., Ph.D., 2009, University of Wisconsin
Anatomic and Clinical Pathology, Hospital of the University of Pennsylvania, 2009-2013
Surgical Pathology, Oregon Health & Science University, Portland, Oregon, 2013-2014
Hematopathology, Oregon Health & Science University, Portland, Oregon, 2014-2015
Anatomic and Clinical Pathology (American Board of Pathology), 2013
Hematopathology (American Board of Pathology), 2015
Areas of interest
Clinical interests: Molecular pathology, hematopathology, and digital pathology
Research interests: The pathogenesis of various types of lymphoma, the effect of molecular events on tumor phenotype and prognosis, and development of novel diagnostic approaches for challenging hematopathology cases.
Select publications (full PubMed bibliography link in Additional Information)
In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. Anekpuritanang T, Klairmont MM, Gradowski J, Hagiwara K, Bailey NG, Chandra PK, Liu Y, Mulder HL, Easton J, Zhang J, Martin MG, Owczarczyk AB, Dunlap J, Fan G, Press RD, Raess PW. Blood Adv.
Molecular Discordance between Myeloid Sarcomas and Concurrent Bone Marrows Occurs in Actionable Genes and Is Associated with Worse Overall Survival.Werstein B, Dunlap J, Cascio MJ, Ohgami RS, Fan G, Press R, Raess PW. J Mol Diagn.
MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. Raess PW, Moore SR, Cascio MJ, Dunlap J, Fan G, Gatter K, Olson SB, Braziel RM. Leukemia & Lymphoma. 2018 Jun. PMID: 28868942.